GlucoTrack, Inc.

GCTK

US45824Q6061

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-28 EDT			5-day change	1st Jan Change
2.11 ^USD	+3.95%		-10.21%	+61.38%

05-16	Glucotrack?s Epidural Glucose Monitoring Sensor Demonstrates Successful 30-Day Safety & Performance in Long-Term Preclinical Study	CI
04-22	GlucoTrack, Inc. announced that it has received $0.5 million in funding	CI

Integrity Applications, Inc. Announces Resignation of Eugene Naidis as Vice President of R&D, Effective December 31, 2020

October 08, 2020 at 05:01 pm

On October 4, 2020, Eugene Naidis, Vice President of R&D, provided notice of resignation from Integrity Applications, Inc., effective December 31, 2020, for personal reasons.

Latest news about GlucoTrack, Inc.

Glucotrack?s Epidural Glucose Monitoring Sensor Demonstrates Successful 30-Day Safety & Performance in Long-Term Preclinical Study	05-16	CI
GlucoTrack, Inc. announced that it has received $0.5 million in funding	04-21	CI
Glucotrack Expanding Glucose Monitoring Technology to Epidural Space	04-16	MT
GlucoTrack, Inc. Announces Expansion of its Continues Glucose Monitoring Technology to Epidural Glucose Monitoring	04-16	CI
Glucotrack Announces Increased Sensor Longevity for Its Implantable Continuous Blood Glucose Monitor	04-02	CI
GlucoTrack, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Glucotrack, Inc Announces Appointment of Luis Malavé as Chairman of Its Board of Directors	02-13	CI
GlucoTrack Says Implantable Glucose Monitor Safe With High Level of Accuracy; Shares Rise	01-02	MT
GlucoTrack, Inc. Announces Early Accuracy Data for its Implantable Continuous Glucose Monitor	01-02	CI
GlucoTrack, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
GlucoTrack Finance Chief Jolie Kahn Resigns, James Cardwell Named New CFO	23-10-12	MT
GlucoTrack, Inc. Announces Executive Changes	23-10-12	CI
Glucotrack, Inc. Appoints Erin Carter to Its Board of Directors and as Chair of Its Audit Committee	23-08-31	CI
GlucoTrack, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Glucotrack, Inc. Announces Positive Data from Feasibility Study for Implantable Continuous Glucose Monitor	23-07-25	CI
Certain Common Stock of GlucoTrack, Inc. are subject to a Lock-Up Agreement Ending on 13-JUN-2023.	23-06-12	CI
GlucoTrack, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
GlucoTrack Completes $10 Million Share Sale	23-04-17	MT
Top Midday Decliners	23-04-13	MT
GlucoTrack Prices $10 Million Securities Offering; Shares Slump	23-04-13	MT
Wall Street Set to Open Higher; Jobless Claims Rise as Producer Price Index Comes in Lower Than Expected	23-04-13	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	23-04-13	MT
US Futures Nudge Higher Ahead of Jobless Claims Report	23-04-13	MT
Top Premarket Decliners	23-04-13	MT
GlucoTrack Plans Underwritten Public Offering of Common Shares	23-04-13	MT

GlucoTrack, Inc. is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is developing an implantable continuous glucose monitoring (CGM) for use by Type 1 diabetes patients as well as insulin-dependent Type 2 patients. It is developing an implantable continuous blood glucose monitor (CBGM). This product is designed to have an approximately two-year implant longevity without the requirement for any wearable components. The CBGM utilizes an intravascular approach, in which the device is implanted subcutaneously and connected to a lead that is placed directly into a blood vessel. This facilitates continuous blood glucose measurements with zero lag time. The Company is also developing the Glucotrack CBGM a companion mobile application and a cloud-based solution to provide real time, data-driven personalized tools to effectively help a user manage their diabetes and assist healthcare providers with making treatment decisions.

Sector

Biotechnology & Medical Research

Calendar

2024-06-20 - American Diabetes Association Scientific Symposium - Poster No 1010-P

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GLUCOTRACK, INC.	+61.38%	10.86M
MODERNA, INC.	+54.05%	63.85B
IQVIA HOLDINGS INC.	-2.02%	41.83B
LONZA GROUP AG	+40.01%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.42%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.69B
BIO-TECHNE CORPORATION	+2.89%	12.73B
UNITED THERAPEUTICS CORPORATION	+22.40%	12.11B
MEDPACE HOLDINGS, INC.	+27.49%	12.07B